T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

Product Manager - Residual DNA products

Full-TimeUpdated on 10/23/2026
$125k - $180k
Senior
Bachelor's, Master's
Pleasanton, CA, USA
In PersonFully onsite; travel up to 25%, including international travel.
ProductProduct Management

About the job

Requirements
  • An advanced degree plus 6 years of experience, or a bachelor's degree plus 8 years of experience, in scientific instruments, laboratory products, or the life sciences industry; multiple years of product management experience are preferred.
  • A preferred field of study is Analytical Chemistry, Biochemistry, Life Sciences, Business, Marketing, Engineering, or a related field.
  • Demonstrated success in developing and executing product strategies and roadmaps.
  • Strong analytical and financial acumen, including the ability to build business cases and analyze market opportunities.
  • Experience leading cross-functional teams and collaborating across organizations.
  • Expertise in gathering and synthesizing Voice of Customer insights.
  • Strong project management skills and the ability to manage multiple initiatives simultaneously.
  • Experience with new product development processes and product lifecycle management.
  • Strong written and verbal presentation and communication skills.
  • Proficiency in analyzing market trends, competitive intelligence, and industry dynamics.
  • Ability to travel up to 25%, including internationally.
  • Experience managing and developing team members is preferred.
  • Experience with customer relationship management systems and digital marketing tools.
  • A proven track record of successful product launches and commercialization.
  • Ability to work effectively in a global, matrix organization.
Responsibilities
  • Guide product strategy and innovation for the Residual DNA analysis portfolio.
  • Shape the product vision and lead development and execution of product roadmaps aligned with market demands and customer needs.
  • Own the portfolio's strategy and lifecycle, translating customer challenges and market dynamics into business priorities and commercial opportunities.
  • Conduct market research, analyze competitive landscapes, and gather customer insights to inform strategic decisions.
  • Develop business cases, define product requirements, and oversee product launches from conception to commercialization.
  • Build and maintain relationships with stakeholders across research and development, marketing, sales, and technical teams.
  • Prioritize a customer-centric approach to product development.
  • Help shape scientific discovery solutions that address customer challenges, influence product strategy, drive growth initiatives, and contribute to the company's mission.
Desired Qualifications
  • Multiple years of product management experience.
  • Leadership experience managing and developing team members.

About the company

T

Thermo Fisher Scientific

View

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Yahoo Finance
Oct 28th, 2026
Teen wins $25K for low-cost airborne bacteria sampler at Thermo Fisher Junior Innovators Challenge

Bailey Quinn Frank, 15, of Fort Lauderdale, Florida, won the $25,000 Thermo Fisher Scientific ASCEND Award, the top prize at the 2026 Thermo Fisher Scientific Junior Innovators Challenge. Thermo Fisher Scientific and Society for Science announced the winners in Washington, D.C. Frank built a low-cost environmental DNA sampler that uses a small fan and filter paper to collect airborne bacteria. She says it could help rural communities monitor health threats where resources for disease surveillance are limited. The 30 finalists, chosen from nearly 2,000 applicants, shared more than $100,000 in awards. Four other top winners each received $10,000, including twin brothers Henry and Jack Grover, 14, who developed a hydrogel sprayer to stop wildfires reigniting.

Yahoo Finance
Oct 23rd, 2026
Illumina stock is up 172.2% in a year, but is Thermo Fisher the cheaper buy?

Illumina and Thermo Fisher Scientific both sell to drug developers and patient-testing labs, but their financial profiles split evenly. Illumina stock returned 172.2% over the past year, against 21.7% for Thermo Fisher. Illumina raised its 2026 revenue forecast to a midpoint of $4.62 billion on July 30, driven by clinical markets. Thermo Fisher raised its 2026 guidance on October 21 to $47.7 billion–$48.2 billion, after third-quarter revenue rose 9% to $12.14 billion. Illumina leads on margins and debt: a 66.4% gross margin against 40.8%, and debt equal to 6.2% of market value against 17.0%. Thermo Fisher leads on price and growth. Illumina trades at 49.3 times trailing earnings, against 36.0 for Thermo Fisher, which also grew revenue 7.2% against 4.9%.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher Q3 revenue rises 9.1% to $12.14B, beating estimates on pharma and AI

Thermo Fisher beat Wall Street expectations in the third quarter of 2026, with sales up 9.1% year on year to $12.14 billion. Analysts had expected $11.96 billion. Adjusted earnings per share were $6.68, 4.3% above the $6.40 estimate. Operating margin rose to 18.6% from 17.5% a year earlier, and organic revenue grew 6%. Chief executive officer Marc Casper credited a broad recovery in end markets, high single-digit growth in pharma services, and strong electron microscopy demand from the semiconductor industry. Asia Pacific posted low double-digit growth. The company expects further momentum in pharma services and clinical research, and plans to integrate AI across its products. Bioscience reagents remain soft. Shares trade at $697.65, up from $687.37 before the results.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher shares rise just 1% despite Q3 revenue of $12.14B and higher guidance

Thermo Fisher Scientific shares rose about 1% after the company reported third-quarter 2026 results, a muted reaction to a clean earnings beat. Revenue reached $12.14 billion, up about 9% from $11.12 billion a year earlier, while adjusted earnings per share were $6.68. Net income, excluding extra items, rose about 7% to $1.72 billion. Adjusted operating margin expanded by 120 basis points to 24.5%, and the company raised its full-year earnings guidance. Laboratory Products & Biopharma Services grew 10% organically, with margins up 100 basis points. Organic revenue growth for 2026 is only 4%, and a planned microbiology divestiture will remove $645 million of revenue.

Yahoo Finance
Oct 21st, 2026
Thermo Fisher raises 2026 organic growth outlook to 4% on strong biopharma demand

Thermo Fisher Scientific raised its full-year organic revenue growth outlook to 4% on its third-quarter earnings call on October 21, 2026. The company said it beat its third-quarter revenue expectations and kept its fourth-quarter guidance at 4%. Chief executive officer Marc Casper said demand in pharma and biotech markets stayed strong, building on the improvement seen in the second quarter. Artificial intelligence built into its lab hardware cuts manual setup time by about 90%, Casper said. He added that the integration of Clario, a recent acquisition, is going smoothly, with revenue synergies expected as its clinical development tools join Thermo Fisher's wider offering.